Standout Papers

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19 2024 202635
  1. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19 (2024)
    Hiroshi Yotsuyanagi, Norio Ohmagari et al. JAMA Network Open

Immediate Impact

9 from Science/Nature 27 standout
Sub-graph 1 of 8

Citing Papers

Mapping the effectiveness and risks of GLP-1 receptor agonists
2025 Standout
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
2024 StandoutScience
4 intermediate papers

Works of Yuko Tsuge being referenced

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
2022
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
2022
and 1 more

Author Peers

Author Last Decade Papers Cites
Yuko Tsuge 192 53 35 49 11 242
Genki Ichihashi 189 53 35 48 7 238
Kawthar Mohamed 160 47 61 57 12 263
Qin Mao 203 64 47 34 5 284
Pauline Brun 189 48 39 26 8 269
Victoria Dulière 204 50 39 26 8 284
Paola Magro 164 27 33 22 13 265
Zheng Yao Low 152 20 73 53 12 269
Jarosław Przybyciński 128 38 63 23 11 274
Collin S Hill 168 26 46 18 9 211
Minoosh Shabani 149 53 29 30 15 250

All Works

Loading papers...

Rankless by CCL
2026